Shield Therapeutics Receive Positive Opinion On Lead Asset Feraccru

23rd February 2018 | Shield Therapeutics plc

Shield Therapeutics (LON:STX), the AIM Listed developer and distributor of treatments for Iron Deficiency Anaemia, has received an endorsement from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The EMA have adopted a positive opinion for the marketing authorisation approval of their lead asset Feraccru (Ferric Maltol) to be extended to include treatment of all adults with iron deficiency (ID) with or without anaemia.

If ratified by the European Commission in the next 2-3 months, this step will see the treatment made available to a broader group of patients.


Below is a short video we filmed with CEO Carl Sterrit, for professional investors